Researchers from Thomas Jefferson University are one step closer to developing a vaccine against the AIDS disease. Led by Matthias J. Schnell, PhD, director of the Jefferson Vaccine Center, the researchers found that a rabies virus–based vaccine administered to monkeys protected against the simian equivalent of the HIV virus (SIV). The data were published in the journal Vaccine.
The researchers previously showed that a rabies-based vaccine expressing HIV and SIV antigens protective against a chimeric HIV/SIV virus in monkeys. In this study, they used highly attenuated rabies virus vaccine vectors to protect against challenge with the highly pathogenic SIVmac251. This type of SIV virus causes a more similar disease in monkeys compared to human infection with HIV-1. In addition, it is difficult to protect monkeys against AIDS-like disease after challenge with SIVmac251.
Two vaccine strategies were used: immunization with a recombinant rabies virus expressing SIVmac239GagPol, or a combination of that and a rabies virus expressing SIVmac239Env. Both strategies induced neutralizing antibody production, CD8+ T cell responses, and increased protection. Although the combination with Env helped immediately following the infection, the long-term benefits were minimal. However, it was surprising that the rabies-based vaccine was able to induce such potent anti-SIV humoral responses.
"Although we can't yet block the infection, we showed that we can protect against disease," said Schnell. "We also saw significant antibody activity against the virus, which is promising. In addition, this is a very simple approach that only took two immunizations."
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.